CaNCURE Mentors

Omid Farokhzad, M.D.

Associate Professor of Anesthesia
Harvard Medical School

Biography: Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center and a member of the Dana Farber/Harvard Cancer Center. Dr. Farokhzad’s research is focused on the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored approximately 100 papers and holds more than 125 issued/pending US and International patents. The technologies that Dr. Farokhzad has developed with collaborators at HMS and MIT have formed the basis for: 1) a new class of targeted nanoparticles for treatment of important human diseases including cancer and cardiovascular disease; 2) a new class of synthetic nanoparticle vaccines for prophylactic and therapeutic applications and 3) a new class of integrative combination nanomedicines for synergistic treatment of cancers, inflammation/pain, and infectious diseases. These technologies formed the foundational platform for the launch of three biotechnology companies: BIND Therapeutics, Selecta Biosciences, and Blend Therapeutics.

Research and Expertise: Our research seeks novel nanomaterials and nanotechnologies in order to develop advanced drug delivery systems with the promise to improve health care. Highly interdisciplinary and translational, our research is focused on multifunctional, nanoparticle-based drug delivery systems. We seek to improve nanoparticle synthesis and formulation and its therapeutic efficacy. Additionally, we develop robust engineering processes to accelerate translation of nanoparticle-based drugs into the drug development pipeline. At the same time, we emphasize a fundamental understanding of the interface between nanomaterials and biological systems.



Featured Publications



SiRNA nanocomplexes